KRAS and neoplasm: PIK3CA was also shown to regulate tumor immunogenicity and a genetic ablation of PIK3CA rendered mutant KRAS/TP53 driven pancreatic tumors more immunogenic by increasing the expression of major histocompatibility complex class 1 (MHC 1) and CD80, both of which are needed for T-cell stimulation (Sivaram et al., 2019).